Objective:
To synthesize evidence on the pathophysiology, prognostic value, and clinical interpretation of serum lactate in patients with cardiogenic shock.
Approach:
- Evidence Review: Investigators reviewed clinical trials, registries, observational studies, and studies involving temporary mechanical circulatory support.
Key Findings:
- Admission lactate is associated with shock severity and mortality.
- Lactate thresholds of approximately 3 to 3.5 mmol/L indicate higher risk of short-term mortality.
- A baseline lactate level of 5 mmol/L predicts 30-day mortality in acute myocardial infarction-related cardiogenic shock.
- Serial lactate monitoring reflects metabolic recovery and response to therapy.
- Lactate measured 8 hours after presentation predicts 30-day mortality more accurately than baseline lactate.
- Reductions in lactate during the first 12 to 24 hours are associated with improved survival.
- Complete lactate clearance is a strong predictor of survival.
- Persistent hyperlactatemia despite adequate device flow indicates poor outcomes.
Interpretation:
Lactate levels reflect disease severity and should be interpreted in the context of clinical conditions, not as standalone measures.
Limitations:
- The review is a narrative synthesis of heterogeneous sources.
- Lactate values should be interpreted within the broader clinical context.
Conclusion:
Trajectory-based lactate assessment may provide important information for risk stratification and therapeutic guidance.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
